Medartis Holding AG (SIX: MED) announced that its shareholders approved all substantive proposals by the Board of Directors with significant majorities exceeding 90.9% at the Annual General Meeting (AGM) held on April 23, 2026, in Basel, Switzerland. The meeting saw strong participation, with 10,545,669 shares validly represented, accounting for 77.4% of total share capital.
Seven board members standing for re-election received resounding endorsement, each securing more than 93.8% support from represented votes. Yang Xu was newly elected to the Board of Directors with 99.7% endorsement and will join the Finance and Audit Committee. Chairman Marco Gadola continues to lead the board, while Jennifer Dean did not seek re-election after two years with Medartis. Shareholders also confirmed Damien Tappy and Marco Gadola as members of the Human Resources and Compensation Committee (HRCC).
Shareholders granted discharge to board members for their governance during the 2025 term and approved, through separate votes, the proposed maximum total remuneration for both the Board of Directors and the Executive Management Board, including fixed and variable components. The 2025 management report and annual financial statements received nearly unanimous approval at 99.99%, while the remuneration report was approved by 91.0% in a consultative vote. Additionally, the sustainability report gained strong endorsement from 99.2% of represented shares, confirming Medartis' commitment to transparent ESG practices.
The assembly confirmed the re-election of Neovius AG as independent voting representative and Ernst & Young AG as statutory auditors. For a detailed listing of all resolutions, please visit this link.
Medartis also announced upcoming investor calendar events: an Investor Visitor Day on June 4, 2026, in Basel on the fringes of the FESSH Hand Surgery Congress, providing institutional investors an opportunity to engage with management; the first-half 2026 results publication on August 18, 2026; and the next Annual General Meeting scheduled for April 22, 2027, at the company's headquarters.
The strong shareholder support reflects confidence in Medartis' strategic direction and governance. The election of Yang Xu brings fresh expertise to the board, particularly in finance and audit, which is critical for the company's continued growth in the medical device industry. The high approval rates for the sustainability report underscore the importance of ESG factors to investors, a trend increasingly vital in the healthcare sector.
Medartis, headquartered in Basel, Switzerland, is a leading manufacturer of medical devices for surgical fixation of bone fractures and joint replacement. The company employs approximately 1,400 individuals across 12 countries and offers products in over 60 countries globally.
